Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis

Barnabas, 2006, Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses, PLoS Med, 3, e138, 10.1371/journal.pmed.0030138 Bergeron, 2008, Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France, Int J Technol Assess Health Care, 24, 10, 10.1017/S0266462307080026 Boot, 2007, Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands, Vaccine, 25, 6245, 10.1016/j.vaccine.2007.05.061 Brisson, 2007, The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada, Vaccine, 25, 5399, 10.1016/j.vaccine.2007.04.086 Choi, 2007, Developing a model of the transmission of HPV and development of HPV-related disease de Kok, 2009, Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands, J Natl Cancer Inst, 101, 1083, 10.1093/jnci/djp183 Elbasha, 2007, Model for assessing human papillomavirus vaccination strategies, Emerg Infect Dis, 13, 28, 10.3201/eid1301.060438 French, 2007, Strategies for the introduction of human papillomavirus vaccination: modelling the optimum age- and sex-specific pattern of vaccination in Finland, Br J Cancer, 10.1038/sj.bjc.6603575 Goldhaber-Fiebert, 2008, Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination, J Natl Cancer Inst, 100, 308, 10.1093/jnci/djn019 Goldie, 2004, Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine, J Natl Cancer Inst, 96, 604, 10.1093/jnci/djh104 Mandelblatt, 2002, Benefits and Costs of Using HPV Testing to Screen for Cervical Cancer, J Am Med Assoc, 287, 2372, 10.1001/jama.287.18.2372 Jit, 2007, Estimating natural history parameters for human papillomavirus infection from epidemiological data Jit, 2008, Economic evaluation of human papillomavirus vaccination in the United Kingdom, BMJ, 337, a769, 10.1136/bmj.a769 Kim, 2005, Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy, J Natl Cancer Inst, 97, 888, 10.1093/jnci/dji162 Kohli, 2007, Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UK, Br J Cancer, 96, 143, 10.1038/sj.bjc.6603501 Kulasingam, 2007, A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program, Sex Health, 4, 165, 10.1071/SH07043 Kulasingam, 2003, Potential health and economic impact of adding a human papillomavirus vaccine to screening programs, J Am Med Assoc, 290, 781, 10.1001/jama.290.6.781 Regan, 2007, Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia, Sex Health, 4, 147, 10.1071/SH07042 Sanders, 2003, Cost-effectiveness of a potential vaccine for human papillomavirus, Emerg Infect Dis, 9, 37, 10.3201/eid0901.020168 Taira, 2004, Evaluating human papillomavirus vaccination programs, Emerg Infect Dis, 10, 1915, 10.3201/eid1011.040222 Usher, 2008, Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model, Vaccine, 26, 5654, 10.1016/j.vaccine.2008.07.098 Van de Velde, 2007, Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty, Am J Epidemiol, 10.1093/aje/kwk059 Brisson, 2009, Economic evaluation of human papillomavirus vaccination in developed countries, Public Health Genomics, 12, 343, 10.1159/000214924 Insinga, 2008, Structural differences among cost-effectiveness models of human papillomavirus vaccines, Expert Rev Vaccines, 7, 895, 10.1586/14760584.7.7.895 Kim, 2008, Modeling cervical cancer prevention in developed countries, Vaccine, 26, K76, 10.1016/j.vaccine.2008.06.009 Marra, 2009, Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review, Pharmacoeconomics, 27, 127, 10.2165/00019053-200927020-00004 Villa, 2006, Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18, Vaccine, 24, 5571, 10.1016/j.vaccine.2006.04.068 Viscidi, 2004, Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica, Cancer Epidemiol Biomarkers Prev, 13, 324, 10.1158/1055-9965.EPI-03-0166 Trottier, 2008, Type-specific duration of human papillomavirus infection: implications for human papillomavirus screening and vaccination, J Infect Dis, 197, 1436, 10.1086/587698 af Geijersstam, 1998, Stability over time of serum antibody levels to human papillomavirus type 16, J Infect Dis, 177, 1710, 10.1086/517428 Canfell, 2004, The predicted effect of changes in cervical screening practice in the UK: results from a modelling study, Br J Cancer, 91, 530, 10.1038/sj.bjc.6602002 Goldie, 2003, A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine, Int J Cancer, 106, 896, 10.1002/ijc.11334 Myers, 2000, Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis, Am J Epidemiol, 151, 1158, 10.1093/oxfordjournals.aje.a010166 Goldhaber-Fiebert, 2007, Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination, Popul Health Metr, 5, 11, 10.1186/1478-7954-5-11 Hughes, 2002, The theoretical population-level impact of a prophylactic human papilloma virus vaccine, Epidemiology, 13, 631, 10.1097/00001648-200211000-00006 Anderson, 1991 Garnett, 2005, Role of herd immunity in determining the effect of vaccines against sexually transmitted disease, J Infect Dis, 191, S97, 10.1086/425271 Brisson, 2006, Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs, Med Decis Making, 26, 434, 10.1177/0272989X06290485 Dietz, 1988, Epidemiological models for sexually transmitted diseases, J Math Biol, 26, 1, 10.1007/BF00280169 Kretzschmar, 1998, The effect of pair formation and variable infectivity on the spread of an infection without recovery, Math Biosci, 148, 83, 10.1016/S0025-5564(97)10008-6 Chen, 2008, Mind the gap: the role of time between sex with two consecutive partners on the transmission dynamics of gonorrhea, Sex Transm Dis, 35, 435, 10.1097/OLQ.0b013e3181612d33 Chen, 2009, A metapopulation modelling framework for gonorrhoea and other sexually transmitted infections in heterosexual populations, J R Soc Interface, 6, 775, 10.1098/rsif.2008.0394 de Villiers, 2004, Classification of papillomaviruses, Virology, 324, 17, 10.1016/j.virol.2004.03.033 Choi, 2009, Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom, Vaccine Kim, 2008, Health and economic implications of HPV vaccination in the United States, N Engl J Med, 359, 821, 10.1056/NEJMsa0707052 Rowhani-Rahbar, 2009, Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine, Vaccine, 27, 5612, 10.1016/j.vaccine.2009.07.027 Sénécal, 2006, Psychological impact of cervical screening and condylomas: an epidemiological study (PISCES) Boily, 1991, Sexual contact patterns between men and women and the spread of HIV-1 in urban centres in Africa, IMA J Math Appl Med Biol, 8, 221, 10.1093/imammb/8.4.221 Insinga, 2009, Epidemiologic natural history and clinical management of human papillomavirus (HPV) disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model, BMC Infect Dis, 9, 119, 10.1186/1471-2334-9-119 Statistics Canada. Annual Demographic Statistics. Minister of Industry. Catalogue no.91-213 2006;. Ferguson, 2000, More realistic models of sexually transmitted disease transmission dynamics: sexual partnership networks, pair models, and moment closure, Sex Transm Dis, 27, 600, 10.1097/00007435-200011000-00008 Poolman, 2008, Vaccination and the evolutionary ecology of human papillomavirus, Vaccine, 26, C25, 10.1016/j.vaccine.2008.04.010 Fairley, 2009, Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women, Sex Transm Infect, 85, 499, 10.1136/sti.2009.037788 Brisson, 2003, Economic evaluation of vaccination programs: the impact of herd-immunity, Med Decis Making, 23, 76, 10.1177/0272989X02239651 Kjaer, 2009, A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions, Cancer Prev Res (Philadelphia, PA), 2, 868, 10.1158/1940-6207.CAPR-09-0031 Paavonen, 2009, Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women, Lancet, 374, 301, 10.1016/S0140-6736(09)61248-4 The Canadian Community Health Survey (CCHS). Cycle 3.1; 2005. www.statcan.gc.ca/concepts/health-sante/cycle3_1/index-eng.htm. Ades, 2008, Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia, Int J Cancer, 122, 2820, 10.1002/ijc.23459 Richardson, 2003, The natural history of type-specific human papillomavirus infections in female university students, Cancer Epidemiol Biomarkers Prev, 12, 485 Mayrand, 2006, Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST), Int J Cancer, 119, 615, 10.1002/ijc.21897